Share this article on:

Pharmacokinetic Interaction Between Nevirapine and Rifampicin in HIV-Infected Patients With Tuberculosis

Ribera Esteban; Pou, Leonor; Lopez, Rosa Ma; Crespo, Manuel; Falco, Vicenç; Ocaña, Imma; Ruiz, Isabel; Pahissa, Albert
JAIDS Journal of Acquired Immune Deficiency Syndromes: December 15th, 2001
Brief Report: PDF Only

To determine whether rifampicin reduces serum concentrations of nevirapine and whether nevirapine modifies serum concentrations of rifampicin, levels of these agents were determined at steady state by high-performance liquid chromatography in 10 HIV-infected patients with tuberculosis. The median area under the curve (AUC)0-12h of nevirapine before and after rifampicin was 56.2 and 32.8 µg/ml per hour, respectively (p = .04). This represents a 31% reduction in serum nevirapine concentrations. The Cmax decreased from 5.6 to 4.5 μg/ml (p = .04), which represented a 36% reduction. A 21% decrease in the Cmin was not statistically significant. Exposure to rifampicin did not significantly differ between those patients who were receiving and were not receiving nevirapine. However, our study shows that rifampicin reduces serum exposure to nevirapine. The clinical implications for this reduction remain to be established. Given that the lowest trough serum concentration of nevirapine exceeded by more than 40 times the protein binding adjusted median infective dose (IC50) of wild-type HIV in all patients, we suggest that there is no need to increase nevirapine dosage when it is given with rifampicin.

Address correspondence and reprint requests to Esteban Ribera, Servicio de Enfermedades Infecciosas, Hospital Vall d'Hebron, Paseo Vall d'Hebron 119-129, 08035 Barcelona, Spain; e-mail:

Manuscript received April 25, 2001; accepted September 30, 2001.

© 2001 Lippincott Williams & Wilkins, Inc.